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Introduction
Chronic obstructive pulmonary disease (COPD) is a 
significant cause of death and disability in both developed 
and developing countries. It is increasing in frequency and 
demands increasing utilisation of healthcare resources. 
Objective
To revise the South African guideline for the management 
of COPD based on emerging research that has informed 
updated recommendations.
Key points
(I) Smoking is the major cause of COPD, HIV 
infect ion,  exposure to biomass  fuels  and 
tuberculosis are important additional factors. 
(II) Spirometry is important for the diagnosis of 
COPD.
(III) COPD is either undiagnosed or diagnosed too 
late, thus limiting the benefit of therapeutic 
interventions; performing spirometry in at-risk 
individuals will help to identify COPD early. 
(IV) COPD should be managed as a multisystem 
disease  with  at tent ion to  comorbidi t ies , 
particularly cardiovascular disease. 
(V) Primary and secondary prevention are the most 
cost-effective strategies in managing COPD. 
Smoking cessation as well as avoidance of other 
risk factors can prevent the development of 
COPD and retard disease progression. 
(VI) Bronchodi lators  [ long-act ing muscarinic 
antagonist (LAMA) or long-acting beta-2 agonists 
(LABA)] are the mainstay of pharmacotherapy, 
relieving dyspnoea, reducing acute exacerbations, 
reducing rate of disease progression and improving 
quality of life.
(VII) Inhaled corticosteroids (ICS) are recommended 
in patients with frequent exacerbations and 
those with peripheral blood eosinophilia and 
have a synergistic effect with bronchodilators 
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in improving lung function, quality of life and 
reducing exacerbation frequency.
(VIII) Oral corticosteroids are not recommended for 
maintenance treatment of COPD.
(IX) A therapeutic trial of oral corticosteroids to 
distinguish corticosteroid responders from non-
responders is not recommended.
(X) Acute exacerbations of COPD contribute 
significantly to health care costs, accelerates loss 
of lung function and increases mortality. A short 
course of oral corticosteroids (5 days) has been 
shown to be beneficial in acute exacerbations.
(XI) Antibiotics are indicated during acute exacerbations 
associated with purulent sputum.
(XII) Lifestyle modification, pulmonary rehabilitation 
(PR), pneumococcal vaccination and annual 




A working group of clinicians and clinical researchers 
revised and updated the previous guidelines based on 
a detailed review of recent literature, particularly of 
studies performed in South Africa. The level of evidence 
supporting the recommendations are based on the 2019 
GOLD guidelines (1).
Benefits, harms and costs
The position paper pays particular attention to cost-
effectiveness in South Africa and promotes optimal care 
for COPD. It promotes smoking cessation and selection 
of treatment based on objective evidence of benefit. It also 
rejects a nihilistic or punitive approach, even in those who 
are unable to break the smoking addiction.
Recommendations
These include primary and secondary prevention; early 
diagnosis, grading of severity, use of pharmacotherapy, 
pulmonary rehabilitation (PR), and management of 
complications and co-morbidities. Advice is provided on 
the management of acute exacerbations, prescription of 
long-term domiciliary oxygen, guidelines for air travel, 
indication for lung volume reduction surgery (LVRS) and 
lung transplantation (LT).
Validation
The COPD Working Group comprised experienced 
pulmonologists representing University departments in 
South Africa and from private practice. 
Definition
COPD is a defined by GOLD as: “A common, preventable and 
treatable disease, that is characterized by persistent respiratory 
symptoms and airflow limitation that is due to airway and/or 
alveolar abnormalities usually caused by significant exposure to 
noxious particles or gases.” “The chronic airflow limitation that 
is characteristic of COPD is caused by a mixture of small airways 
disease and parenchymal destruction, the relative contributions of 
which vary from person to person.” (1,2).
Epidemiology of COPD  
COPD is one of the leading causes of morbidity and 
mortality in the world. It is estimated that there are 
currently over 380 million cases in the world, a significant 
proportion of whom are undiagnosed. The prevalence of 
COPD is projected to rise owing to increased exposure to 
risk factors and population ageing (1,3). A recent meta-
analysis of 123 COPD studies estimated that the global 
prevalence was 11.7% (8.4–15.0%) (3). In Africa the 
estimated prevalence is 13.4% (IQR, 9.4% to 22.1%) (4).
The Burden of Obstructive Lung Disease (BOLD) 
study (5) that investigated the prevalence of COPD in 
various countries showed that COPD prevalence varied 
considerably in different countries, with a range of 6–19% 
for Stage ≥2 COPD (clinically significant disease) and 
12–26% for Stage ≥1 COPD. Cape Town had the highest 
prevalence of stage ≥2 COPD (19% overall, 22% male and 
17% female), which may be greater than the general South 
African prevalence because of the higher incidence of smoking, 
occupational dust exposure, indoor pollution and prior 
tuberculosis in the area studied. Unlike other chronic diseases, 
COPD mortality for both men and women is increasing. The 
Global Burden of Disease Study has projected that COPD, 
which was ranked 6th as the cause of death in 1990, will become 
the third leading cause of death by 2020 (6,7).
Risk factors
Tobacco smoking is the most prevalent aetiological factor 
for COPD. However non-tobacco related factors and the 
interactions with tuberculosis, HIV, and biomass smoke 
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play important roles (8). This is especially important in 
low income countries and may even supersede the effect 
of tobacco smoke where tobacco smoking is uncommon. 




Alpha-1 antitrypsin deficiency (AATD) is a rare but well 
characterised genetic risk factor (9). Although many genes 
have been associated with COPD—none other than 
AATD have been directly causally linked (10,11). There 
is, however, a familial tendency for COPD in smoking 
family members highlighting the importance of the gene vs. 
exposure link (12).
Lung growth and development
Early childhood and even in utero exposures are recognised 
as important predictors of peak lung volumes and the 
subsequent development of COPD. Maternal tobacco 
smoking, malnutrition, poor lung growth owing to problems 
in utero and exposure during childhood is associated with 
airflow obstruction in adulthood (13,14).
Gender
COPD prevalence and mortality is greater among men 
than women, and reflects previous smoking patterns. 
The prevalence is now equalising in developed countries. 





COPD is more common in smokers and ex-smokers than 
in non-smokers. Cigarette smokers have more respiratory 
symptoms, lung function abnormalities, faster decline 
in FEV1, and COPD mortality than non-smokers. The 
starting age, total pack-years smoked and current smoking 
status are predictive of COPD morbidity and mortality 
(16). The annual decline of forced expiratory volume in one 
second (FEV1) in smokers varies from 55–100 vs. about 30 
mL/year in non-smokers (17). However, not all smokers 
develop clinically significant COPD so genetic factors must 
modify risk (18). The oft-quoted figure of only 15% of 
smokers developing COPD is probably an under-estimate 
(19). Pipe and cigar smokers have greater COPD morbidity 
and mortality rates than non-smokers, although their rates 
are lower than those for cigarette smokers.  Passive or 
environmental tobacco smoke (ETS) may also contribute to 
COPD (20,21). Smoking during pregnancy may predispose 
to asthma and COPD by decreasing lung growth and 
development in the foetus (22).
Cannabis
Smoking cannabis is associated with higher frequency of 
chronic bronchitis and a dose-related airflow obstruction 
especially when combined with tobacco (23,24).
Occupational dusts and chemicals
Occupational dust and chemical exposure has long 
been identified as an independent cause of COPD (25). 
The population-based National Health and Nutrition 
Examination Survey (NHANES III) utilising spirometry 
as far back as 2002, estimated that the fraction of COPD 
attributable to work was 19% overall and 31% among 
never-smokers (26).
Indoor air pollution
The burning of biomass and fossil fuels (wood, animal dung, 
crop residues and coal) in open fires or poorly functioning 
stoves in poorly ventilated spaces lead to very high levels 
of indoor air pollution. Almost half the world’s population, 
and 90% of rural families use biomass or coal as their main 
source of energy for cooking and heating resulting in over 
3 billion people exposed (27,28). Biomass exposure begins 
in early childhood and may continue throughout life with 
significant negative health effects including COPD (29,30). 
There remains some controversy over the definition of 
biomass induced chronic lung disease (31).
Outdoor air pollution
Environment air pollution, mainly from motor vehicle 
emissions in cities and biomass smoke (from bush and forest 
fires), is associated with loss of lung function (32-34). 
Infections
There is now unequivocal evidence of the association 
between previous tuberculosis and COPD (35-37), which 
in many settings is stronger than the association between 
smoking and COPD (38-40). The mechanism of chronic 
airflow limitation is likely to involve the small airways 
primarily, and may be distinct from smoking related 
COPD (41,42); however, the two conditions may co-exist 
within an individual. The association between tuberculosis 
and COPD is strongest in high incidence countries, 
the young and never smokers (35,37). Post-tuberculosis 
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bronchiectasis should be excluded as a cause of airflow 
limitation, before tuberculosis-associated obstruction is 
presumed.
Childhood respiratory infections are associated with 
reduced lung function and increased respiratory symptoms 
in adulthood (43). Several studies have shown that 
previous pulmonary tuberculosis may lead to COPD (44). 
HIV infection has been shown to accelerate the onset of 
smoking-related emphysema (45,46). In addition, viral and 
bacterial infections may contribute to the pathogenesis and 
progression of COPD (47).
Socioeconomic status
Poor socio-economic status is strongly linked to COPD 
and likely promoted by smoking, biomass exposure, poor 
nutrition, and intrauterine growth retardation (48).
Aim of this position paper
The purpose of this paper is to improve the care of patients 
with COPD at all levels of the health system in South 
Africa and to provide information that will assist in early 
recognition and optimal treatment (49,50).
Recognition of disease (early diagnosis and 
staging of severity)
The diagnosis of COPD should be considered in any 
patient with chronic progressive dyspnoea and/or chronic 
cough (with or without sputum production) with a smoking 
history of more than 10 pack-years and/or other risk factors 
for COPD. A detailed history of exposure during childhood, 
occupation, as well as tobacco, HIV and previous TB is 
important. All smokers should be considered at risk and 
have screening spirometry where this is available.
Correct diagnosis, and in particular the differentiation 
of COPD from other causes of patient’s symptoms, is 
important to ensure correct treatment. Clinical features 
that assist in the diagnosis of each condition are outlined 
in Table 1. Early detection of COPD, effective smoking 
cessation interventions, optimal pharmacotherapy, lifestyle 
modification and PR slow the decline in pulmonary function 
and improve the quality of life.
Clinical evaluation should include a history of exposures 
and risk factors, an assessment of breathlessness (e.g., 
the modified MRC dyspnoea scale (Figure 1), symptoms 
[COPD Assessment Test (CAT)] (Figure 2), the occurrence 
and severity of exacerbations, and co-morbid conditions 
Table 1 Distinguishing features of chronic obstructive pulmonary 
disease (COPD) and asthma
Features suggesting a diagnosis of COPD
• Persistent dyspnoea on effort with cough and wheeze 
• History of smoking or exposure to other risk factors
• Slow progression
• Abnormal post bronchodilator spirometry 
Features that suggest the presence of asthma
• Young age at onset
• Diurnal or day-to-day variability and seasonal variation
• Presence of atopy and/or allergic rhinitis
• Significant bronchodilator responsiveness
Additional considerations in the diagnosis of asthma and COPD
• Asthma and COPD may co-exist, and distinguishing them 
may be difficult
• Asthmatics who smoke may have an accelerated decline in 
lung function
• COPD patients may have a raised eosinophil count and 
bronchodilator responsiveness
COPD, chronic obstructive pulmonary disease.
Grade Description
0 Not troubled by breathlessness except with strenuous exercise
1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill
2 Walks slower than people of the same age on the level because of breathlessness or 
has to stop for stop for breath when walking at own pace
3 Stops for breath after walking about 100 m or after a few minutes on the level
4 Too breathless to leave the house or breathless when dressing or undressing
Figure 1 Modified Medical Research Council (UK) dyspnoea scale.
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Figure 2 CAT is reproduced with permission from GSK.
that could complicate management. Physical examination 
may reveal signs of hyperinflation and airway obstruction 
but may be normal. Co-morbid conditions should also be 
sought.
Spirometry
Spirometry is critical for the detection, assessment and 
management of patients with COPD. It is encouraged 
and must be performed by adequately trained persons 
using a spirometer of approved standard and quality that 
is calibrated frequently (51). Measurements used in the 
diagnosis of COPD are pre- and post-bronchodilator FEV1, 
FVC and FEV1/FVC%. 
Detection of airflow obstruction
The presence of a post-bronchodilator FEV1/FVC 
ratio of less than 70% confirms the presence of airflow 
obstruction. The FEV1 is usually reduced (less than 80% 
of predicted value) and is used as a measure of severity. 
Most patients with symptomatic COPD have a reduced 
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Table 2 Grading of the severity of airflow limitation 
Severity grade Severity grade FEV1*
1 Mild FEV1 ≥80% of predicted
2 Moderate 50%≤ FEV1 <80% of predicted
3 Severe 30%≤ FEV1 <50% of predicted
4 Very severe FEV1 <30% of predicted
*, post bronchodilator FEV1. FEV1, forced expiratory volume in one second.
FEV1, but many patients with significantly reduced FEV1 
have no symptoms.
Assessment of bronchodilator responsiveness with short-
acting bronchodilators
Spirometry should be performed before, and 10 to 
30 minutes after, 4 puffs of a short-acting beta2-agonist 
bronchodilator (e.g., salbutamol). An improvement in FEV1 
≥12% from baseline and ≥200 mL indicates significant 
bronchodilator responsiveness.  Larger bronchodilator 
responses (>400 mL) are suggestive of asthma but are 
also seen in many patients with COPD (52). However, 
in general, the larger the improvement, the greater the 
likelihood that the diagnosis is asthma, however this 
cannot be used as the sole diagnostic criteria for asthma 
and  the clinical profile should be borne in mind (Table 1). 
Normalisation of spirometry after a bronchodilator excludes 
the diagnosis of COPD. 
Assessment of severity of COPD
To establish the severity of airflow obstruction, FEV1 
is expressed as a percentage of predicted values. The 
European Community for Steel and Coal (ECSC) (53) 
or the NHANES III reference equations (54) are 
recommended for routine use in South Africa, but 
the newer Global Lung Initiative (GLI) equations are 
becoming more widely used (55). The validity and 
appropriateness of the correction for ethnicity is an area 
of much debate currently. Caution should be exercised 
when borderline lung function values are elicited before 
labelling an individual with disease. The GLI equations, 
using lower limits of normal or suggested correction 
factors for ethnic differences (amounting to approximately 
12% lower values for FVC in Africans or African-
Americans) have been reported in some series, and a 
correction factor (multiplication of the spirometric value 
by 0.9 for African blacks and 0.95 for people of mixed or 
Asian ethnicity) could be applied (56). Measurement of 
peak expiratory flow (PEF), while helpful in asthma, is not 
an appropriate test for diagnosing COPD and does not 
distinguish obstructive from restrictive lung disease. 
The assessment of severity of COPD is based on 
spirometry measures and clinical indicators including 
severity of dyspnoea and symptoms, functional impairment 
and 6-minute walking distance (6MWD) (57). Assessment 
of dyspnoea (as per the mMRC score) and exacerbation 
history in the past twelve months as criteria to be used 
to grade severity is recommended to guide appropriate 
pharmacological treatment. Primary treatment should be 
with a long-acting bronchodilator to relieve dyspnoea. 
Additional anti-inflammatory treatment is recommended if 
there is a history of frequent exacerbations (≥2 per year).  
Grading of severity also guides prognosis and level 
of treatment. The complex 2019 GOLD algorithm has 
been simplified for use across all levels of care (primary to 
specialist level care) in South Africa. A mild, moderate and 
severe COPD approach has been advocated in keeping with 
GOLD A, B and D. Details of the grades of severity are 
provided in Table 2.
Monitoring disease progression
Progression of COPD is monitored using serial spirometry, 
dyspnoea grading and frequency of exacerbations. Rapid 
progression may be due to acute exacerbations or cardiac 
disease, pulmonary embolism and pneumothorax. 
Chest radiography
A chest radiograph is recommended at the time of diagnosis 
of COPD. It may show evidence of hyperinflation, but a 
normal chest radiograph does not exclude the diagnosis. It 
is also useful for detecting alternative condition such as lung 
cancer or interstitial pulmonary fibrosis. 
4414 Abdool-Gaffar et al. South African Thoracic Society COPD guideline
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2019;11(11):4408-4427 | http://dx.doi.org/10.21037/jtd.2019.10.65
Prevention of disease progression 
Avoidance of occupational and environmental pollution, 
including passive tobacco smoke exposure is important, 
particularly in susceptible persons: pregnant women, infants 
and children, persons with alpha-1 antitrypsin deficiency, 
and those with established COPD.
Smoking cessation is the primary measure that has been 
shown to slow the progression of COPD, and is one of 
the most cost-effective interventions in health care (58). 
All smokers must be encouraged to stop smoking. Health 
care workers should be familiar with smoking cessation 
measures and promote these among their patients (59). 
Although respiratory symptoms may initially worsen when 
an individual quits, the short and  long-term benefits are 
substantial. Of particular importance is the reduction in 
cardiovascular and cancer risk and the slowing of lung 
function decline (60,61).
Smoking cessation programmes
The South African Thoracic Society clinical practice 
guidelines contain a detailed approach to smoking cessation 
in the South African context (59). For all smokers, 
behavioural modification is recommended in order to 
break the habit of smoking. For smokers with high levels 
of nicotine addiction, a tailored approach of either nicotine 
replacement therapy or targeted pharmacological therapy 
(varenicline or bupropion) may be more effective. Relapse is not 
uncommon due to the strong behavioural aspect of smoking 
and the addictive nature of nicotine. In individuals living in low 
income settings, behavioural and psychological support may be 
more important than just the provision of NRT (62).
Alleviation of breathlessness and improvement 
in effort tolerance 
Inhaled therapy is the preferred route of administration 
of COPD medication. Inhaler technique, choice of the 
most appropriate device and combination of medication 
are essential to ensure adequate delivery of medication and 
reduce side effects.
Bronchodilators
Bronchodilators are the mainstay of the treatment 
of COPD and include inhaled beta-2 agonists and 
muscarinic antagonists. Oral theophylline additionally 
has some bronchodilator effect. Individuals vary in their 
responsiveness to each, and combinations may have additive 
effects (63-65). Commence treatment in symptomatic patients 
with an inhaled short-acting bronchodilator on a PRN basis 
(mild COPD/GOLD A). Thereafter, increase treatment 
stepwise to include inhaled long-acting bronchodilators, 
slow-release theophylline (moderate COPD/GOLD B) and 
ICS in those with more severe symptoms and exacerbations 
(severe COPD/GOLD D) (Table 3). 
Inhaled short-acting beta-2 agonists
These agents have a rapid onset of action and are only of 
value in short-term relief of symptoms. 
Inhaled LABA
There are several LABAs, and are available either as 
single agents or in combination (salmeterol, formoterol, 
indacaterol, vilanterol, olodaterol). LABAs are more 
effective for symptom control than regular short-acting 
beta-2 agonists. Their use as monotherapy is recommended 
in moderate COPD (GOLD B) without ICS (unlike in 
asthma where they must only be used in combination with 
an ICS). LABAs improve symptoms, reduce exacerbations, 
reduce rescue therapy requirements and improve exercise 
capacity (Evidence A) (63,66).
Inhaled muscarinic antagonists  
Anti-muscarinic agents are effective bronchodilators for 
COPD as the disease is associated with increased vagally 
mediated bronchoconstriction. Ipratropium bromide is 
a short-acting agent with a peak bronchodilator effect at 
approximately 40 minutes and between 4–6 hours duration 
of action. Tiotropium bromide is a LAMA with a slow onset 
of peak bronchodilation but a 24-hour duration of action 
facilitating once-daily administration. Glycopyrronium 
bromide, another once-daily LAMA, has been shown to have 
equivalent efficacy to tiotropium, but with a faster onset of 
action. Anti-cholinergic agents may be more effective than 
beta-2 agonists in many patients and have few side effects but 
may result in a dry mouth and urinary retention. 
Ipratropium bromide is prescribed for as-needed use for 
symptom relief in COPD and can also be used 4–6-hourly 
as a maintenance bronchodilator agent although it is far 
less effective than the once daily drugs (67). Tiotropium 
or glycopyrronium may be used as a first-line long-acting 
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Table 3 Treatment choices based on severity of disease
Severity of 
disease
Defining clinical features Treatment recommendations
Mild COPD  
(GOLD A)
Confirmed spirometric post-bronchodilator obstruction (commonly 
will have mild to moderate severity of lung function (FEV1 >50%)
a;  
minimal symptoms on effort (mMRC <2), CAT<10b; infrequent 
exacerbations (1 per year)c
Short acting bronchodilator (SABA or SAMA) as 
needed for symptomatic relief
Moderate COPD 
(GOLD B)
Confirmed spirometric post-bronchodilator obstruction (lung 
function may be preserved or significantly reduced, FEV1 >50%)
a; 
significant symptoms on effort (mMRC ≥2), or CAT >10; infrequent 
exacerbations (1 per year)
Long acting bronchodilator either LAMA or LABA; 
if inadequate response, try alternative agent or 
add a second bronchodilator; if no symptomatic 
benefit, withdraw second agentd
Severe COPD 
(GOLD D)
Confirmed spirometric post-bronchodilator obstruction (commonly 
will have severe lung function reduction FEV1<50%)
a; severe 
symptoms on effort (mMRC ≥2), CAT >10; frequent exacerbations: 
2 outpatient or 1 inpatient in past 12 months
Single bronchodilator LAMAe; dual bronchodilator: 
LAMA/LABA or alternatively LABA/ICSf; if not 
responding to dual agents, referral to specialist is 
advisedg
a, lung function is not used to grade the severity of COPD or inform therapy. The severity of obstruction will provide guidance as to how 
severe the airflow limitation is but correlates poorly with symptoms and mortality. b, the mMRC evaluates dyspnoea on effort, and the 
CAT (COPD assessment test) is a composite score of symptoms including cough, dyspnoea, etc. c, exacerbations are loosely defined as 
significant symptoms warranting additional treatment with corticosteroids and or antibiotics. d, theophylline can be considered for moderate 
or severe COPD based on availability of alternative inhaled therapies. e, if Initiating therapy, start with LAMA. If previously on a single 
agent, use dual bronchodilator. f, dual bronchodilator (LAMA/LABA) is the first-choice recommendation for dual agent, as there is a greater 
reduction in exacerbations compared to LABA/ICS with less risk of pneumonia [rate ratio 0.89 (0.83–0.96)] NNT 20 (95% CI, 13–44) (66).  
The cost of LAMA/LABA is significantly higher than LABA/ICS which should be considered in the treatment choice where resources are 
limited. g, in the severe group, see Table 4 for suggested ‘phenotyping options’ to guide add-on therapy at specialist level. COPD, chronic 
obstructive pulmonary disease; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SABA, short 
acting beta-2 agonist; SAMA, short acting muscarinic antagonist; CAT, COPD Assessment Test; LAMA, long-acting muscarinic antagonist; 
LABA, long-acting beta-2 agonists; ICS, inhaled corticosteroids; NNT, number needed to treat.
Table 4 Treatment approach according to ‘Phenotypes’ in severe COPD
Clinical phenotype Management strategy
Dyspnoea phenotype With increasing dyspnoea, one should increase bronchodilator therapy
Exacerbator phenotype LAMA or combination long-acting bronchodilators → add on ICS and/or 
Roflumilast and/or a macrolide
Co-existing asthma (blood eosinophil count >300/mm3) Consider ICS
Severe/very severe COPD + chronic bronchitis phenotype & 
frequent exacerbations
Consider adding roflumilast or a macrolide 
COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids. 
bronchodilator treatment in COPD, or may be used 
in combination with a LABA because of their different 
mechanisms of action. LAMAs have been shown to improve 
quality of life and reduce exacerbation rates (Evidence A) 
and hospitalisation (Evidence B) (65,68,69).
Combination therapy
The following combination of drugs may be considered 
for patients who remain symptomatic despite monotherapy 
or who have severe COPD or frequent exacerbations. 
However, combination therapy can increase costs 
substantially. Some combinations of inhaled drugs are 
available in a single inhaler device.
Compared to LABA alone the addition of a LAMA 
resulted in (64):
 Reduction in exacerbation rate (Evidence B);
 Small but significant improvement in SGRQ 
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(Evidence A);
 Improvement in FEV1 (Evidence A).
Compared to LABA alone adding an ICS (70,71):
 Reduces the number of acute exacerbations in patients 
with moderate to severe COPD (Evidence A);
 Improves FEV1 (Evidence A);
 Improves health-related quality of life (Evidence A);
 Increases the risk of oral candidiasis and pneumonia 
(Evidence A).
Compared to LABA/ICS the LAMA/LABA combination 
(FLAME study) (72):
 Reduced exacerbation rate RR 0.89 (95% CI, 0.83–
0.96);
 Lengthened time to first exacerbation 71 vs. 
52 days (95% CI, 46–57 days);
 Reduced pneumonia: 3.2% vs. 4.8%, P=0.02.
Compared to LABA/ICS, LABA/LAMA & LAMA alone, 
the LABA/LAMA/ICS combination (IMPACT Study) (73):
 Increases FEV1, reduces exacerbation frequency, 
improves symptoms (Evidence A).
Nebuliser treatment
This is an alternative for lung function grade 3 and 4 
patients with poor inhalation technique and/or acute 
dyspnoea.
 Nebulised ipratropium plus beta-2 agonist can be 
used up to 3 or more times daily (74,75). While 
there are distinct advantages, nebulisers tend to be 
overused.
 Patients requiring chronic nebuliser therapy should 
have specialist assessment.
Theophylline
Theophylline, a methylxanthine, has similar bronchodilator 
effects to beta-2 agonists. It improves quality of life 
(Evidence B). Oral administration is an advantage for some 
patients (76). Limitations include toxicity (particularly in 
the elderly), drug interactions and variable metabolism 
and compared to LABAs are less effective (77). The 
recommended dose of oral slow-release theophylline 
is 200–400 mg twice a day or 400–800 mg at night, 
and should not be exceeded without monitoring blood 
levels. This drug should preferably be used together with 
inhaled bronchodilator therapy, and not as monotherapy. 
Combination tablets containing theophylline and other 
bronchodilators, or sedatives are not recommended.
Inhaled corticosteroids (ICS)
There is no conclusive evidence for the use of ICS as 
monotherapy in COPD (63,70). In the chronic phase of 
COPD, corticosteroids should only be given by the inhaled 
route and always in combination with bronchodilators. ICS 
therapy has been linked to the development of pulmonary 
tuberculosis (78-80) and should be used in the appropriate 
patient group and with caution.
There continues to be controversy regarding the use 
of ICS in COPD but some aspects are clear: ICS therapy 
has been associated with an increased risk of pneumonia 
(Evidence A) (71). However, the absolute increase in 
incidence of pneumonia is 0–3% (81). When pneumonia 
does occur, it does not appear to be life-threatening 
(82-84). However, when combined with a LABA, the ICS/
LABA combination is more effective than either alone 
in improving lung function and health status, as well as 
reducing exacerbations (Evidence A) (63,70). There is 
growing evidence of a COPD eosinophilic phenotype that 
responds better to ICS. It is recommended that a blood 
eosinophil level above 300 cells/µL defines this responder 
status, with a linear relationship with higher eosinophil 
counts, i.e., the greater the number the greater the 
improvement in the exacerbation rate (85). 
Adding a LAMA to LABA/ICS also improves lung 
function, patient reported outcomes and exacerbations 
(Evidence A) (73). ICS in combination with a LABA and/
or LAMA should be reserved for patients with a high 
probability of exacerbations during the next year (1). 
Moreover, ICS may be withdrawn and replaced by LABA 
and/or LAMA in low risk patients (1,86). This should 
be done with caution especially in patients with high 
eosinophils or a history of asthma and where an initial 
decline in lung function is expected (86,87).
Oral corticosteroids
The long-term use of oral corticosteroids is strongly discouraged 
given its poor impact on lung function (Evidence C) and major 
side-effects (Evidence A) (1,88). Moreover, the use of an oral 
corticosteroid trial to determine corticosteroid-responsive 
subjects was abandoned many years ago as such a phenotype 
cannot be distinguished (1,89). 
Phosphodiesterase inhibitors  
The oral phosphodiesterase 4 (PDE-4) inhibitors are an 
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alternative class of drugs for COPD. These drugs increase 
concentrations of cyclic adenosine monophosphate (cAMP) by 
inhibiting its PDE-mediated breakdown. Roflumilast, a once 
daily oral medication, is the only PDE-4 inhibitor currently 
approved by the US Food and Drug Administration. 
A number of  tr ials  have been performed using 
Roflumilast or Cilomilast in the management of COPD. 
A Cochrane review concluded that this class of drugs 
demonstrated small, but significant improvement in 
lung function (FEV1 mean difference of 45 mL), and 
reduced the likelihood of exacerbation (OR 0.77; 95% 
CI, 0.71–0.83), which translated into six additional people 
remaining exacerbation free, for every 100 people treated 
in the trial period (Evidence A). They were found to 
have little effect on either quality of life or symptoms. 
However, non-serious side effects are common, especially 
gastrointestinal symptoms and headaches, with Roflumilast 
being associated with weight loss, insomnia and depressive 
symptoms. Of note, is that the treatment groups of many 
controlled trials were more likely to withdraw due to 
intolerable side-effects (90).
Patients most likely to benefit from Roflumilast have 
been identified as those with more severe COPD who 
have chronic bronchitis with frequent exacerbations (2 or 
more per year) (91). Using Roflumilast in addition to other 
bronchodilators in this population has shown mixed results, 
with a recent study failing to demonstrate a reduction in 
moderate and/or severe exacerbations (92). This has to be 
compared to a previous trial in a similar population group, 
which showed a small, but statistically significant reduction 
in exacerbations and hospital admissions when added to 
inhaled therapies (93), with both studies demonstrating 
high numbers of non-serious side effects, and almost twice 
as many discontinuations. 
Use of PDE-4 inhibitors in acute exacerbations of COPD 
has not been demonstrated to be of benefit, and a recent 
study showed equivocal results in airway inflammation (94).
 
Alpha-1 antitrypsin augmentation therapy
Intravenous a lpha-1 ant i trypsin augmentat ion is 
recommended (Evidence B) in non-smoking patients, 
known with alpha-1 deficiency with an FEV1 35–60%. The 
cost of medication limits the availability (1).
Mucolytics and mucokinetic agents
A Cochrane review of 26 studies (19 using N-acetylcysteine), 
concluded that mucolytics may produce a small reduction 
in acute exacerbations, and may have a small beneficial 
effect on overall quality of life, while appearing to be 
relatively safe (95) (Evidence B). A recent randomized trial 
of Lysozyme (a mucolytic) failed to show benefit in terms 
of exacerbation rate, or improvement in FEV 1 or CAT 
(symptom) scores, but appeared well tolerated (96). 
Based on the heterogeneity of studies, and reduced 
benefit in more recent studies, we do not recommend the 
routine use of mucolytics or mucokinetics for COPD. It is 
unclear whether certain phenotypes will be identified in the 
future, which may benefit more from these therapies. 
Airway clearance
A Cochrane review showed airway clearance techniques 
to be safe in acute exacerbations of COPD, but the effects 
although significant were small, and based on small studies 
of low quality. Reported effects included a decreased 
need for ventilation and reduced hospital stay, but no 
short-term improvement in quality of life or long-term 
decrease in exacerbations. Airway clearance techniques 
in stable COPD appeared to have no short-term benefit 
on exacerbations, but did improve quality of life, and may 
reduce hospitalization in the long-term (97).
A further systematic review showed airway clearance 
techniques did not improve resting lung function or gas 
exchange, while continuous (5 min) chest wall percussion 
reduced FEV1. However, in patients with copious secretions, 
mechanical vibration and positive expiratory pressure 
(PEP) mask therapy could increase sputum clearance, while 
the latter as well as intrapulmonary percussive ventilation 
(IPV) may reduce requirements for NIPPV in hypercapnic 
respiratory failure (98). 
We therefore do not recommend stand-alone, routine 
airway clearance for outpatient COPD management, and 
although safe, evidence does not support routine airway 
clearance in acute exacerbations. However, selected patients 
who present with excessive secretions or an ineffective 
cough may benefit from airway clearance interventions. 
If required, airway clearance using PEP techniques have 
greater benefit over other airway clearance methods. 
Venesection  
Polycythaemia occurs in about 6% of COPD patients (99). 
This secondary polycythaemia has not been robustly shown 
to be associated with worse outcomes in COPD (99). 
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Physiological studies have shown that phlebotomy in 
polycythaemic patients with COPD increases the maximum 
achievable workload, primarily due to an increased 
cardiac output (100), as well as lowers viscosity with a 
corresponding improvement in cerebral perfusion and 
mental function (101,102). Patients with polycythaemia 
should be referred for investigation and treatment including 
venesection. 
Assessment of response to therapy
The FEV1 is useful as a diagnostic and prognostic tool 
and is also of value in monitoring disease progression. 
It is not as useful for assessing response to treatment. 
Other lung function measurements to monitor response 
include inspiratory capacity (IC), residual volume (RV) and 
functional residual capacity (FRC) (103). The response 
to treatment can also be gauged by the improvement in 
dyspnoea, and the mMRC dyspnoea scale (Figure 1) is used 
to quantify the degree of dyspnoea. The 6MWD test can be 
used to assess response to therapy as well (Appendix B).
PR and education 
PR is  a  comprehensive interdiscipl inary tai lored 
intervention including exercise and education for people 
with COPD with the aim of promoting physical and 
psychological well-being, self-efficacy, health enhancing 
behaviours. PR has consistently shown to increase 
functional capacity, decrease dyspnoea and improve quality 
of life (104,105). Programmes usually involve structured 
exercise training, education, nutritional intervention, 
and psychosocial support. PR does not improve lung 
function, lung mechanics or gas exchange, but targets 
the systemic manifestations of COPD such as sarcopenia 
and deconditioning. Participants of such programmes 
undergo a comprehensive assessment by their doctor and 
physiotherapist, in order to tailor the programme to their 
individual needs (106).
Underlying medical conditions need to be adequately 
managed and medications should be optimised. A minimum 
of 20 sessions should be given at least three times per week 
to achieve physiologic benefits; twice weekly supervised 
plus one unsupervised home session may also be acceptable 
(107,108). There is insufficient evidence of benefit currently 
to recommend the use of hybrid models of PR including 
telehealth (105). Rehabilitation can be undertaken in 
resource-limited settings using supervised walking as a 
major component, however there is a need to develop 
contextualised recommendations in resource limited settings.
Prevention and treatment of acute exacerbations 
of COPD
Definition, natural history and diagnosis of exacerbations
An exacerbation is defined as an increase in symptoms of 
COPD above the usual day-to-day variation experienced 
by the patient and that necessitates a change in treatment. 
Exacerbations vary in both severity and frequency. They can 
be classified as: 
(I) Mild—those needing additional short-acting 
bronchodilators (SABDs) only;
(II) Moderate—those needing SABDs and antibiotics 
+/− oral corticosteroids;
(III) Severe—those needing hospitalisation or emergency 
room visits.
Exacerbations severely affect quality of life, may be 
associated with permanent worsening of COPD, account 
for a large percentage of the direct costs associated with 
the treatment of COPD, accelerate disease progression and 
increase mortality. The most common cause of exacerbations 
is tracheobronchial infections, usually viral in aetiology.
Acute exacerbations must be distinguished from other 
diseases and complications of COPD (including pneumonia, 
pneumothorax, congestive heart failure, arrhythmias and 
pulmonary embolism) that require alternative treatment. 
When exacerbations are associated with features of infection 
(pyrexia and purulent sputum), the presence of pneumonia 
and other forms of lower respiratory infection should be 
excluded using a chest radiograph. The aim of therapy for 
acute exacerbations is to prevent further exacerbations and to 
minimise the duration and severity of the current exacerbation. 
Prevention of exacerbations
The following measures have been shown to reduce 
the frequency and/or severity of COPD exacerbations 
(Evidence A) (1):
 Smoking cessation;






 Long-term macrolide therapy.
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Management of exacerbations (1,2,47)
An exacerbation can be managed in either an outpatient or 
inpatient setting depending on severity. 80% or more of 
exacerbations are manageable on an outpatient basis.
Bronchodilators
Short-acting inhaled β2 agonists are the 1
st choice and 
they may be combined with short-acting anticholinergics. 
Nebulisations with short-acting bronchodilators may be 
given 4-hourly (or as often as every 30–60 minutes or 
continuously in severe cases). Multiple actuations of an 
MDI delivered via a large (>500 mL) spacer device may be 
as effective as nebulisation.
Should there be an inadequately sustained response 
to the above treatment, oral or intravenous theophylline 
may be used. However, significant side-effects with the 
methylxanthines may be anticipated. 
Corticosteroids
Corticosteroids should preferably be given orally (as 
effective as intravenous administration). A daily dose 
of 30–40 mg prednisone for 5 days is recommended 
(maximum 7) (109). Tapering is not required. Systemic 
corticosteroids reduce recovery time and hospitalization 
duration (Evidence A).
Antibiotics (see Appendix C, Table S1)
These should be prescribed when there is evidence of 
a severe exacerbation (as evidenced by the 3 cardinal 
symptoms of increased sputum volume, sputum purulence 
and increased dyspnoea) or in those who require ventilation 
(Evidence B) (1). Sputum gram-stain may be helpful by 
confirming the presence of bacterial organisms but is not 
an essential investigation. The organisms most commonly 
involved are Streptococcus pneumoniae, Haemophilus influenzae 
and Moraxella catarrhalis. With the increasing appearance 
of penicillin- and macrolide-resistant pneumococci, and 
beta-lactamase-mediated resistance of H. influenzae and 
M. catarrhalis, local sensitivity data should be considered 
when choosing an antibiotic. Macrolides should be 
avoided in areas where there are high levels of resistance. 
Alternatives are amoxicillin/clavulanate, cefuroxime, or 
fluoroquinolones. The oral route of administration is 
preferred except in severe illness. The duration of treatment 
should be 5–7 days (Evidence A).
Oxygen therapy
Oxygen should be started at 24% or 1–2 L/minute by 
nasal cannula. Increases should be gradual to avoid carbon 
dioxide narcosis. This should be guided by blood gas 
analysis or by the level of consciousness if blood gases are 
not available. The aim should be to maintain the oxygen 
saturation between 88–92%.
Indications for hospitalisation
Severe COPD and or any of the following features:
 Sustained failure to improve on outpatient 
management; 
 Inability to walk between rooms (where previously 
mobile);
 Family and/or physician unable to manage the 
patient at home;
 High-r i sk  co-morbid  condi t ion ,  whether 
pulmonary (e.g., pneumonia) or non-pulmonary;
 Prolonged progressive worsening of symptoms 
before emergency visit;
 Altered mentation;
 Worsening hypoxaemia and new or worsening 
hypercapnia;
 New onset arrhythmia;
 Elderly or frail patient;
 New or worsening right-sided cardiac failure 
unresponsive to outpatient management.
Indications for ICU admission
Pre-conditions for ICU admission:
 Sa t i s f ac tory  funct iona l  s t a tus  be fore  the 
exacerbation (patient coped with activities of daily 
living); if not known, the patient should be given 
the benefit of the doubt.
 Possible need for mechanical ventilation, i.e., PaO2 
<6.7 kPa (50 mmHg) on room air, arterial blood 
pH <7.3, and confusion.
 The presence of a reversible factor. Examples are 
infections, bronchospasm, oxygen-induced carbon 
dioxide narcosis, sedative administration, heart 
failure or other associated illnesses.
Ventilatory support 
Ventilatory support must be considered for the patient with 
one or more of the following features:
 Exhaustion, confusion, coma;
 pH <7.3 and declining (respiratory acidosis);
 Respiratory or cardiac arrest;
 Inability to clear secretions.
Modalities of ventilatory support include invasive 
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(mechanical ventilation) and non-invasive continuous 
positive airways pressure (CPAP) or BiPAP techniques. 
Patients considered suitable for non-invasive ventilation 
(NIV) are those who are able to protect their airway and 
clear their airway secretions. Indications for NIV include the 
following (all criteria should be met):
 Respiratory rate >30 breaths/minute;
 pH <7.35;
 PCO2 >6.7 kPa (>50 mmHg);
 PaO2 <6.7 kPa (<50 mmHg) on room air.
Contra-indications to NIV include haemodynamic 
instability, decreased level of consciousness or poor co-
operation, vomiting and excessive secretions. Appearance 
of any of these features in a patient undergoing NIV who 
still needs ventilation is an indication for intubation and 
mechanical ventilation.
Non-invasive positive pressure ventilation in acute 
exacerbations has been shown to improve blood gases and 
pH, reduce in-hospital mortality, decrease the need for 
invasive mechanical ventilation, and decrease the length of 
hospital stay (Evidence A). High-flow nasal oxygen therapy 
may be considered as an alternative to NIV in patients with 
acute exacerbations of COPD. However, there is currently 
only limited evidence for this indication (110).
Adjunct therapies
 Appropriate fluid balance including the judicious use of 
diuretics where clinically indicated;
 Nutrition should be carefully monitored;
 Smoking cessation must be emphasized during the 
exacerbation;
 Prophylaxis for thromboembolism should be instituted 
as patients are at high risk for deep venous thrombosis 
and pulmonary embolism.
Prevention and treatment of complications
The main complications include right heart failure, severe 
exacerbations, pulmonary embolism, pneumothorax, 
erythrocytosis and chronic respiratory failure.
The management of right heart failure
 Identify and treat the precipitating cause. In COPD, 
this may include an acute respiratory infection, 
worsening airflow obstruction (review bronchodilator 
and other treatment) or worsening hypoxaemia from 
additional factors such as re-location to higher altitude 
or a thrombo-embolic event.
 Correction of hypoxaemia with long-term oxygen as 
indicated under long-term oxygen therapy (LTOT), 
see paragraph 10.3) (Evidence D).
 Diuretics (e.g., hydrochlorothiazide or furosemide)  
 Digoxin must be avoided except in the presence of 
atrial fibrillation and/or left ventricular dysfunction/
failure (Evidence C).
 ACE inhibitors and calcium antagonists are not 
indicated for the management of cor pulmonale or 
right ventricular failure (Evidence B).
 Prophylaxis with subcutaneous heparin to prevent deep 
vein thrombosis during periods of exacerbation or 
prolonged immobilisation (Evidence A).
 Chronic treatment with warfarin needs to be 
considered in COPD patients with atrial fibrillation or 
thrombo-embolic complications (Evidence A). There is 
no evidence of benefit when used routinely in patients 
with cor pulmonale secondary to COPD (Evidence C).
Cardioselective beta-blockers are preferred if required for 
management of atrial fibrillation or left sided heart failure 
(Evidence C) (1).
Pneumothorax
The development of a spontaneous pneumothorax must 
be considered when patients with stable COPD suddenly 
deteriorate, as patients with respiratory impairment tolerate 
even a small pneumothorax poorly.
Long-term oxygen therapy (LTOT)
The full benefit is only evident in patients with persistent 
hypoxaemia (with or without hypercapnia) in the stable 
phase of COPD. In such patients, it has been shown to 
reduce the complications of respiratory and right heart 
failure and to improve survival. Patients with COPD and 
moderate exercise-induced oxygen desaturation (SpO2 ≥80% 
for ≥5 minutes and <90% for ≥10 s during a 6-minute walk 
test) should not be prescribed LTOT as benefit has not been 
demonstrated in this group of patients (111).
Indications for LTOT
 Stable, severe COPD (usually but not exclusively with 
an FEV1 <1.5 L and FEV1/FVC <70%) on optimal 
bronchodilator therapy. The decision to prescribe 
LTOT should only be made once the patient has fully 
recovered from an acute exacerbation, usually after 
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6 weeks).
 Arterial hypoxaemia (PaO2 <7.3 kPa or 55 mmHg at sea-
level) or oxygen saturation <88% at rest.
 Smoking cessation for ≥3 months.
Hypoxaemia must be confirmed by arterial blood gases 
performed while the patient is breathing room air. Following 
exacerbations of COPD, spirometry and PaO2 may continue 
to improve for up to 3 months. Therefore, these should 
ideally be checked in all patients on 2 occasions at least 
1 month, and preferably 3 months, apart before prescribing 
LTOT. Continued smoking reduces the efficacy of 
treatment and is a contra-indication to oxygen therapy. 
Worsening hypercapnia caused by hypoventilation is an 
occasional complication of oxygen therapy in patients 
with severe COPD and hypercapnic respiratory failure. 
Regular follow-up by a suitably experienced physician and 
ready access to technical advice, either through a private 
contractor or a hospital department, must be available. 
Assessment of adherence is essential.
Oxygen prescription
Oxygen is administered by facemask or nasal cannula for 
a total of at least 16 hours per 24-hour day. A flow rate of 
1–2 L/min. is used, the rate being determined in each 
case by arterial blood gas determinations. Oximetry may 
be used for follow-up checks. Oxygen can be delivered by 
oxygen concentrators or by cylinders. Concentrators are 
more convenient and cost effective but require an electricity 
source with additional electricity costs. Portable oxygen 
systems include bottled oxygen with flow-saving devices and 
portable concentrators. With these systems, patients do not 
have to be confined to home.
Palliative symptomatic oxygen therapy
Oxygen given for short periods to relieve breathlessness in 
hypoxic patients with COPD does not influence the natural 
progression of the disease and is therefore not routinely 
recommended. Patients who desaturate at night should be 
assessed for sleep apnoea and treated appropriately.
Sleep in COPD
Sleep-related breathing disorders  are  present  in 
approximately 40% of patients with COPD (112). 
Significant night-time hypoxaemia cannot be predicted from 
measurement of daytime blood gas and pulmonary function 
tests, but if the daytime PaO2 is ≥8 kPa (60 mmHg), 
nocturnal SaO2 need only be measured if unexplained 
respiratory failure, cor pulmonale or erythrocytosis are 
found. Referral for a full sleep study (polysomnography) 
and a specialised opinion should only be considered if sleep-
disordered breathing is suspected (i.e., daytime hyper-
somnolence and other symptoms of sleep deprivation, or a 
strong history of loud snoring with apnoeic events). LTOT, 
prescribed for daytime hypoxaemia, must be used during sleep.
Air travel in patients with severe COPD
COPD patients who travel by commercial aircraft put 
themselves at risk for a range of complications. Respiratory 
incidents comprise 9–10% of airborne emergencies. 
Therefore, the need to travel needs to be balanced against the 
potential risks. Potential travellers with COPD should have 
stable disease (no recent exacerbations, hospitalisations or acute 
illnesses). Co-morbid disease increases the risks of in-flight 
emergencies, i.e., ischaemic heart disease, congestive cardiac 
failure and cor pulmonale (56% of all in-flight emergencies). 
Potential problems include:
 Hypoxaemia at altitude: stable COPD patients 
with an oxygen saturation (SaO2) of 95% pre-flight 
desaturate to about 86% at a cabin altitude of 2,165 m. 
This worsens to 78% with activity.
 Worsening of existing hypoxia at ground level.
 Pulmonary hypertension.
 Worsening discomfort and dyspnoea at altitude.
 Cardiac dysrhythmias.
 Risk of contracting a respiratory infection.
 Pneumothorax from large bullae.
The most practical evaluation includes room air SaO2 
measurements pre-flight. If the SaO2 is less than 92%, 
further assessment is necessary. Available tests are:
 50 m walk test. Those who desaturate will require 
supplemental O2.
 Hypoxic inhalation test. Patients breathe 15% FiO2 
at sea level. Those with significant desaturation will 
need supplemental O2.
 Hypobaric chamber simulating in-flight conditions. 
Their limited availability precludes widespread use 
in assessing patients.
The in-flight requirement would be 2 L/min higher than 
home use, or 2–4 L/min if the assessment indicates the need 
for O2.
Surgery in patient with a diagnosis of COPD
Post-operative pulmonary complications constitute a 
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significant cause of morbidity and mortality. The frequency 
varies from 2–70%. The complications are atelectasis, 
infection (bronchitis and pneumonia),  respiratory 
failure necessitating prolonged mechanical ventilation, 
exacerbation of COPD, bronchospasm and pulmonary 
embolism.
Stratification of risk for pulmonary complications entails 
patient-related as well as procedure-related risk factors. 
Preoperative evaluation depends strongly on taking a 
thorough history and clinical examination. It is reasonable 
to perform a preoperative chest radiograph in patients with 
cardiopulmonary disease and those >50 years undergoing 
high-risk surgery. Pre-operative preparation, optimisation 
of airway function (bronchodilators, steroids, antibiotics and 
chest physiotherapy), smoking cessation, weight reduction 
where applicable, delay of elective surgery if chest infection 
is present, and patient education on deep breathing 
exercises, coughing, pain control and incentive spirometry 
are recommended. Post-operative measures include early 
mobilisation and ambulation, prophylactic lung expansion 
manoeuvres, adequate analgesia and prophylaxis against 
thrombosis.
Surgical interventions for COPD
Surgical techniques that can improve lung function and 





This may be indicated to decompress adjacent lung 
parenchyma if there are large localised bullae. This can be 
performed thoracoscopically and may reduce dyspnoea and 
improve lung function (Evidence C).
Lung volume reduction 
The aim of lung volume reduction is to achieve volume loss 
of the targeted, diseased region(s) and to redirect airflow to 
less affected areas (113,114). Lung volume reduction can be 
achieved by either surgical or endoscopic techniques. LVRS 
entails wedge resection of emphysematous tissue. LVRS 
carries significant morbidity and mortality, but can offer 
survival benefit and increased exercise capacity in selected 
patients with predominantly upper-lobe emphysema, 
an FEV1 >20%, DLCO >20% and low exercise capacity 
(Evidence A) (115). There has been a significant decline 
in the number of LVRS’s performed, both locally and 
internationally. This is mostly because of the modest benefit, 
strict selection criteria, morbidity and mortality associated 
with major thoracic surgery in patients with compromised 
pulmonary and cardiovascular reserves, and the advent 
of endoscopic lung volume reduction (ELVR) (113). A 
bullectomy (which can be performed thoracoscopically) is 
sometimes indicated to decompress adjacent lung parenchyma 
and potentially improve lung functions in patients with large 
localised bullae (Evidence C) (1).
ELVR refers to a bronchoscopic procedure which 
induces volume loss to improve pulmonary mechanics 
and compliance, thereby reducing the work of breathing. 
Globally, this technique is increasingly used as treatment 
for advanced emphysema, with the objective of obtaining 
similar functional advantages to surgical lung volume 
reduction, while decreasing risks and costs. The two most 
commonly used modalities with the largest evidence base 
are endobronchial valves and coils.
In certain selected patients with severe hyperinflation 
(RV >150%) and no interlobular collateral ventilation, 
the unilateral placement of a device with the intention 
of achieving complete lobar collapse has been shown to 
significantly increase lung function, quality of life and 
exercise capacity (Evidence B) (116).
Lung transplantation (LT)
LT is an established therapy for advanced COPD and can 
provide extended survival and excellent quality of life. 
COPD is the most common indication for LT worldwide, 
accounting for 40% of all transplants. Access to LT is 
limited and is currently offered only at major centres in 
South Africa: Johannesburg and Cape Town (117). The 
variability in the natural course of COPD can make it 
difficult to predict when patients should be referred for LT. 
The BODE index (derived from measurements of body 
mass index, degree of airflow obstruction, dyspnoea score 
and exercise capacity) can be used to predict mortality (57); 
this can be balanced against the risk of the transplant. 
Data from the International Society for Heart and Lung 
Transplantation (ISHLT) registry show a median survival 
of ~6 years for patients who undergo transplantation for 
COPD (118). 
Suitable patients may be referred for LT when the:
 Disease is progressive despite optimisation of 
pharmacological management, PR and oxygen 
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therapy;
 Patient is not a candidate for endoscopic or surgical 
LVRS;
 FEV1 <25% of the predicted volume;
 BODE index ≥5;
 There is established hypoxaemic or hypercapnic 
respiratory failure.
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Supplementary
Appendix A Process of guideline revision
The Council of the South African Thoracic Society 
resolved to revise the 2011 COPD guideline and appointed 
a convenor Dr Abdool-Gaffar and co-Chair Prof van 
Zyl-Smit to lead the editorial committee to revise the 
document. Membership of the guideline working group 
comprised representatives from the academic sector and 
private practice. The editorial committee identified areas 
of the guideline that required revision and commissioned 
members of the working group to prepare reviews of 
new data in these areas, with particular reference to the 
content and evidence grading of the latest version of the 
Global Obstructive Lung Disease Guideline [2019]. The 
revised document was compiled by the editorial board 
and circulated to the guideline committee for further 
comment. These comments were considered by the 
editorial committee, and the final draft was then completed 
and approved by the Council of the South African Thoracic 
Society.
Appendix B The 6-minute walk test (6MWT) (75)
The 6MWT is a composite and repeatable test of lung, 
heart and muscle function. Measurement of specific 
exercise-induced outcomes are an extremely important 
adjunct to clinical and lung function evaluation. The 
6MWT does not correlate well with FEV1 but relates to 
the degree of exercise-induced hyperinflation of COPD 
patients and is used extensively as a prognostic indicator for 
patients with COPD, interstitial lung disease or pulmonary 
hypertension. It provides better insight into the degree of 
exercise impairment compared with single evaluations such 
as spirometry or an ECG.
The 6MWT has to be conducted under supervision of a 
trained medical or paramedical person who can recognise 
untoward exercise-induced symptoms. Prior to the test, 
patients have to be evaluated to rule out uncontrolled 
hypertension, ischaemic heart disease, arrhythmias and 
heart failure that may complicate the assessment or 
endanger the patient. These conditions need adequate 
treatment before the 6MWT can be conducted. Patients 
with lower limb arthritis or claudication and those who 
are mentally challenged or old and infirm will not perform 
the test adequately. It can be conducted in any facility that 
has the necessary resuscitation equipment and a straight, 
flat surface of 30 meters or a treadmill. Prior to the test, 
patients need to be counselled to motivate them to achieve 
the greatest distance. They also need to be informed that 
they may rest during the test but that it will be recorded as 
part of their 6MWT walk time. All COPD patients need 
to use their bronchodilators before attempting the 6MWT, 
and they should not be exercised during an infective 
episode or if they are in the immediate recovery phase of an 
exacerbation.
A baseline ECG is done and should be repeated after the 
first effort to record any asymptomatic exercise-induced 
ischaemic changes. The oxygen saturation of blood should 
be measured before and after the test. Determination of 
pulse rate, blood pressure and respiratory rate along with 
the blood oxygen saturation level should be recorded before 
and after the test. A level in the latter <90% or a decline 
>5% will identify those patients who will require oxygen 
during the test. Patients’ opinions as to their degree of 
exhaustion need to be recorded on a Borg scale card which 
provides a semi-quantitative estimation of fatigue and 
dyspnoea. Recovery time should be noted by measuring 
the respiratory and heart rates at 3 and 5 minutes after the 
test. Repeatability of the 6MWD (distance) of 10% should 
be achieved. In this respect, a second or, if required, even a 
third 6MWT should be conducted after periods of rest of 
up to 20 minutes. The 6MWT should be discontinued in 
patients who complain of chest pain, intolerable dyspnoea 
or leg cramps, or appear to be staggering or have an ashen 
or pale appearance. A mean value for males of 464 metres 
and 430 metres for females is the standard for a healthy 
American population. A post-intervention improvement 
of 54 meters above the baseline 6MWD has been found to 
represent a clinically meaningful improvement in COPD 
patients who undergo rehabilitation.
Appendix C Antibiotic use in exacerbations of 
COPD
Chronic bronchitis, with attendant mucociliary dysfunction 
and mucus hypersecretion, is the major pathological 
component that is responsible for the risk of bacterial 
colonisation and acute infective exacerbations of COPD.
Table S1 Recommendations for the antibiotic management of acute exacerbations of COPD based on a classification of bronchitis**
Diagnosis Criteria/risk factors Usual pathogens Recommended treatment*
1. Simple chronic bronchitis Younger patients H. influenzae Aminopenicillin
FEV1 >60% predicted M. catarrhalis Amoxycillin-clavulanic acid
Recent increase in sputum S. pneumoniae Macrolide/azalide/Ketolide
Volume and purulence Beta-lactam resistance possible
2. Complicated chronic 
bronchitis
Older age Same organisms as in 1, but beta-
lactam resistance more common
Amoxycillin-clavulanic acid
FEV1 <60% predicted Sputum Gram stain and culture 
advised
Second or third generation 
cephalosporin
≥4 exacerbations/year Respiratory fluoroquinolone
Recent increase in sputum 
volume and purulence
3. Complicated chronic 
bronchitis with chronic 
bronchial sepsis
As above with purulent 
sputum for long periods in 
year
Same as 2, but also 
Enterobacteriaceae and Pseudomonas 
aeruginosa
Ciprofloxacin
X-ray evidence of structural 
lung disease
Sputum Gram stain Respiratory fluoroquinolone 
Alternative based on result of sputum 
culture and culture advised
*, selection of antibiotic is influenced by knowledge of antibiotic resistance patterns in different areas of the country. **, adapted from 
Grossman RF. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD. Chest 1998;113:249-255. COPD, 
chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second.
